Targovax, a clinical stage company developing immunotherapy treatments for mesothelioma, has announced encouraging results from its phase I/II trial of its drug ONCOS-102. The company reports that when the drug was combined with a standard of care chemotherapy treatment, three out of six of the patients that were treated had positive results. The company’s open…
The post Phase I/II Trial of Immunotherapy Mesothelioma Drug Yields Encouraging Results appeared first on Mesothelioma.net.
from Mesothelioma.net https://ift.tt/2rh9DyI
via IFTTT
Phase I/II Trial of Immunotherapy Mesothelioma Drug Yields Encouraging Results
![Phase I/II Trial of Immunotherapy Mesothelioma Drug Yields Encouraging Results]()
Reviewed by Unknown
on
May 02, 2018
Rating:
No comments: